Details of the Drug Reposition

General Information of This Drug (ID: DMIOFQE)

Drug Name
SOMATOSTATIN   DMIOFQE
Synonyms
51110-01-1; Somiaton; Panhibin; Aminopan; Somatostatin acetate; SRIF; Somatotropin release-inhibiting factor; Somatotropin release-inhibiting hormone; Growth hormone release-inhibiting factor; CCRIS 7071; EINECS 256-969-7; Growth hormone release-inhibiting hormone; AY 24910; Growth hormone release inhibiting factor; Somatostatin 1-14; Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys; NCGC00181005-01; 61950-59-2; [D-Trp8]-SOMATOSTATIN; SCHEMBL3046327
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acromegaly DISCC73U 5A60.0 Approved [1]
Carcinoid syndrome DISDS5OT 5B10 Approved [2]
Discovery agent DISC7DFA N.A. Approved [3]
------------------------------------------------------------------------------------

References

1 A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021 Feb;24(1):1-13.
2 Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes. 2018 Feb;25(1):22-35.
3 Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.